Screening for drug-induced hepatotoxicity in primary mouse hepatocytes using acetaminophen, amiodarone, and cyclosporin a as model compounds: an omics-guided approach.

A. Van Summeren, J. Renes, D. Lizarraga, F.G. Bouwman, J.P. Noben, J.H. van Delft, J.C. Kleinjans, E.C. Mariman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Abstract Drug-induced hepatotoxicity is a leading cause of attrition for candidate pharmaceuticals in development. New preclinical screening methods are crucial to predict drug toxicity prior to human studies. Of all in vitro hepatotoxicity models, primary human hepatocytes are considered as 'the gold standard.' However, their use is hindered by limited availability and inter-individual variation. These barriers may be overcome by using primary mouse hepatocytes. We used differential in gel electrophoresis (DIGE) to study large-scale protein expression of primary mouse hepatocytes. These hepatocytes were exposed to three well-defined hepatotoxicants: acetaminophen, amiodarone, and cyclosporin A. Each hepatotoxicant induces a different hepatotoxic phenotype. Based on the DIGE results, the mRNA expression levels of deregulated proteins from cyclosporin A-treated cells were also analyzed. We were able to distinguish cyclosporin A from controls, as well as acetaminophen and amiodarone-treated samples. Cyclosporin A induced endoplasmic reticulum (ER) stress and altered the ER-Golgi transport. Moreover, liver carboxylesterase and bile salt sulfotransferase were differentially expressed. These proteins were associated with a protective adaptive response against cyclosporin A-induced cholestasis. The results of this study are comparable with effects in HepG2 cells. Therefore, we suggest both models can be used to analyze the cholestatic properties of cyclosporin A. Furthermore, this study showed a conserved response between primary mouse hepatocytes and HepG2 cells. These findings collectively lend support for use of omics strategies in preclinical toxicology, and might inform future efforts to better link preclinical and clinical research in rational drug development.
Original languageEnglish
Pages (from-to)71-83
Number of pages13
JournalOMICS-a journal of Integrative Biology
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • HEPG2 CELLS
  • HUMAN-LIVER
  • MOLECULAR CHARACTERIZATION
  • SCLEROSING CHOLANGITIS
  • METABOLIZING-ENZYMES
  • PROTEOMIC ANALYSIS
  • GENE-EXPRESSION
  • PROTEIN
  • TOXICITY
  • LINES

Cite this